Pharmaceutical company Lupin (NSE:LUPIN, BOM:500257) has received approval from the U.S. Food and Drug Administration for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Lucentis of Genentech.
The US FDA has approved Ranluspec in both vials and pre-filled syringes in strengths of 0.3 mg (0.05 mL of 6 mg/mL) and 0.5 mg (0.05 mL of 10 mg/mL).
The drug is used to treat adults with certain sight problems, including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularisation.